Where Penumbra Stands With Analysts
Portfolio Pulse from Benzinga Insights
Penumbra (NYSE:PEN) has been analyzed by 6 analysts, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $277.17, up from $259.50, with actions ranging from lowering to raising ratings and price targets by firms like JP Morgan and RBC Capital. Penumbra, a medical device manufacturer, showed a revenue growth of 26.8% as of September 30, 2023, but lags in net margin and ROE compared to industry averages. Its debt-to-equity ratio is below industry average, indicating less reliance on debt financing.
February 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Penumbra has received mixed analyst ratings with an updated average 12-month price target of $277.17. The company shows strong revenue growth but faces challenges in profitability and asset efficiency.
The mixed analyst ratings and the increase in the average price target suggest a cautiously optimistic outlook for Penumbra. However, the company's challenges in maintaining profitability and efficiently using assets could temper investor enthusiasm in the short term. The strong revenue growth is a positive sign, but the below-average net margin, ROE, and ROA indicate areas that need improvement. The lower debt-to-equity ratio is a positive aspect, showing less reliance on debt financing.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100